The content on this site is intended for healthcare professionals only
Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of August 8th - 14th, 2022.
Alerts this week cover the FDA’s accelerated approval of fam-trastuzumad deruxtecan-nxki for HER2-mutant NSCLC. In addition to the FDA’s approval of capmatinib for metastatic NSCLC.
He also reminds everybody that ASCO Plenary Series 2022 is coming up this week where he will be reporting in real-time along with the OncoAlert GU faculty.
You can watch Dr Morgan's previous roundup here
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer
Prostate cancer
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
OncoAlert Round Up for August 4th - 10th, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
